Smart MSN-Drug-Delivery System for Tumor Cell Targeting and Tumor Microenvironment Release
Overview
Biotechnology
Authors
Affiliations
Tumor-targeted delivery and controlled release of antitumor drugs are promising strategies for increasing chemotherapeutic efficacy and reducing adverse effects. Although mesoporous silica nanoparticles (MSNs) have been known as a potential delivery system for doxorubicin (DOX), they have restricted applications due to their uncontrolled leakage and burst release from their large open pores. Herein, we engineered a smart drug-delivery system (smart MSN-drug) based on MSN-drug loading, cell membrane mimetic coating, on-demand pore blocking/opening, and tumor cell targeting strategies. The pore size of DOX-loaded MSNs was narrowed by polydopamine coating, and the pores/channels were blocked with tumor-targeting ligands anchored by tumor environment-rupturable -SS- chains. Furthermore, a cell membrane mimetic surface was constructed to enhance biocompatibility of the smart MSN-drug. Confocal microscopy results demonstrate highly selective uptake (12-fold in comparison with L929 cell) of the smart MSN-drug by HeLa cells and delivery into the HeLa cellular nuclei. Further in vitro IC studies showed that the toxicity of the smart MSN-drug to HeLa cells was 4000-fold higher than to the normal fibroblast cells. These exciting results demonstrate the utility of the smart MSN-drug capable of selectively killing tumor cells and saving the normal cells.
Ge H, Wang X, Bai S, Bi Y, Liu F, Sun J Pharmaceutics. 2025; 17(2).
PMID: 40006572 PMC: 11859581. DOI: 10.3390/pharmaceutics17020206.
Li Y, Ji W, Wang C, Chang L, Zhang Q, Gao J ACS Appl Mater Interfaces. 2024; 17(1):689-700.
PMID: 39681510 PMC: 11783531. DOI: 10.1021/acsami.4c18625.
Leng Y, Wu Y, Xiao W, Su X, Liu Z ACS Omega. 2024; 9(48):47428-47435.
PMID: 39651082 PMC: 11618396. DOI: 10.1021/acsomega.4c04502.
Saadh M, Mustafa M, Malathi H, Ahluwalia G, Kaur S, Al-Dulaimi M Med Oncol. 2024; 41(8):201.
PMID: 39001987 DOI: 10.1007/s12032-024-02443-0.
Strategies for enhanced bioavailability of oxime reactivators in the central nervous system.
Prchalova E, Kohoutova Z, Knittelova K, Malinak D, Musilek K Arch Toxicol. 2023; 97(11):2839-2860.
PMID: 37642747 DOI: 10.1007/s00204-023-03587-0.